Gilead’s COVID-19 treatment shows promising results in vulnerable patient populations

18 Apr 2023
www.pmlive.com
Clinical ResultPhase 3Drug Approval
Gilead’s COVID-19 treatment shows promising results in vulnerable patient populations
Preview
Source: PMLiVE
Gilead Sciences has presented positive results from several clinical and real-world evidence studies of its COVID-19 treatment, Veklury (remdesivir), at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).
Results from the phase 3 REDPINE study demonstrated the safety profile of Veklury in patients with moderately and severely reduced kidney function who were hospitalised for COVID-19.
Two real-world studies also examined its efficacy in reducing COVID-19-associated mortality for those living with cancer, as well in reducing hospital readmission for immunocompromised patients infected with dominant variants of concern.
Results from the first analysis, which evaluated nearly 7,500 cancer patients who were hospitalised for severe COVID-19, showed that those who were treated with Veklury within the first two days of admission had a significantly lower risk for mortality compared to those who were not.
In the second analysis of over 4,500 immunocompromised patients, those who received treatment with Veklury had lower risk for hospital readmission at both 30- and 60-day time periods.
Commenting on the positive results, Frank Duff, senior vice president, virology therapeutic area head, Gilead, said: “The breadth of clinical and real-world evidence presented at ECCMID further support the strong efficacy and safety profile of Veklury.
“Since the beginning of the pandemic, Veklury has played a critical role in the treatment of hospitalised patients with COVID-19. The real-world data further demonstrates its role in reducing mortality and hospital readmission rates in vulnerable patient populations, including people living with cancer and other immunosuppressed conditions.”
Veklury is already approved in more than 50 countries worldwide to treat hospitalised patients with COVID-19, and is also recommended by the World Health Organization (WHO) for those with severe COVID-19.
In WHO’s guidelines, which were updated in September last year, patients with severe COVID-19 are defined as those with oxygen saturation less than 90% on room air, signs of pneumonia or signs of severe respiratory distress.
“Remdesivir is an important treatment option for vulnerable patient populations such as the immunocompromised, because it has a well-established safety and tolerability profile and it maintains activity across variants of concern,” said Michele Bartoletti, head of infectious disease unit at Humanitas Research Hospital in Milan and associate professor of Humanitas University.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.